Wanigasooriya, K.; Tyler, R.; Barros-Silva, J.D.; Sinha, Y.; Ismail, T.; Beggs, A.D.
Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers 2020, 12, 1278.
https://doi.org/10.3390/cancers12051278
AMA Style
Wanigasooriya K, Tyler R, Barros-Silva JD, Sinha Y, Ismail T, Beggs AD.
Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers. 2020; 12(5):1278.
https://doi.org/10.3390/cancers12051278
Chicago/Turabian Style
Wanigasooriya, Kasun, Robert Tyler, Joao D. Barros-Silva, Yashashwi Sinha, Tariq Ismail, and Andrew D. Beggs.
2020. "Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors" Cancers 12, no. 5: 1278.
https://doi.org/10.3390/cancers12051278
APA Style
Wanigasooriya, K., Tyler, R., Barros-Silva, J. D., Sinha, Y., Ismail, T., & Beggs, A. D.
(2020). Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers, 12(5), 1278.
https://doi.org/10.3390/cancers12051278